NATCO PHARMA LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,008 INR | -1.98% |
|
+0.20% | +24.21% |
| 09/04 | Natco Pharma Gets US FDA Warning Letter after Inspection of Kothur, India Unit | MT |
| 27/03 | NATCO Pharma Limited Announces Board Appointments | CI |
| Sales 2024 * | 39.19B 470M | Sales 2025 * | 45.13B 541M | Capitalization | 184B 2.21B |
|---|---|---|---|---|---|
| Net income 2024 * | 13.21B 158M | Net income 2025 * | 15.27B 183M | EV / Sales 2024 * | 4.3 x |
| Net cash position 2024 * | 15.67B 188M | Net cash position 2025 * | 31.57B 379M | EV / Sales 2025 * | 3.38 x |
| P/E ratio 2024 * |
14
x | P/E ratio 2025 * |
12.2
x | Employees | 3,946 |
| Yield 2024 * |
0.98% | Yield 2025 * |
1.1% | Free-Float | 46.76% |
More Fundamentals
* Assessed data
More news
Latest transcript on NATCO Pharma Limited
More press releases
| 1 day | -1.96% | ||
| 1 week | +0.20% | ||
| Current month | +5.85% | ||
| 1 month | +3.50% | ||
| 3 months | +14.52% | ||
| 6 months | +26.75% | ||
| Current year | +24.21% |
1 week
995.80
1 059.00
1 month
950.551 059.00
Current year
805.001 108.35
1 year
579.001 108.35
3 years
502.001 189.00
5 years
402.551 189.00
10 years
141.261 189.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 46 | 03/00/03 | |
| Founder | 78 | 19/81/19 | |
| Director of Finance/CFO | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Founder | 78 | 19/81/19 | |
| Chief Executive Officer | 46 | 03/00/03 | |
| Director/Board Member | 70 | 18/14/18 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.02% | 4 M€ | -4.41% | - | |
| 0.01% | 117 M€ | +1.11% | - | |
| 0.00% | 34 M€ | +2.14% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 29/24/29 | 1,008 | -1.98% | 313 682 |
| 26/24/26 | 1,028 | +0.66% | 1,157,262 |
| 25/24/25 | 1,021 | +2.26% | 1,288,313 |
| 24/24/24 | 998.6 | -2.37% | 367,850 |
| 23/24/23 | 1,023 | +1.70% | 639,513 |
Delayed Quote NSE India S.E., April 29, 2024 at 01:34 pm IST
More quotes
Natco Pharma Limited is an India-based vertically integrated pharmaceutical company with focus on research and development. The Company is engaged in in the development, manufacturing and commercialization of complex pharmaceuticals that target specific therapeutic areas. It specializes in catering to niche markets and offering solutions to address complex medical needs. It owns nine manufacturing facilities across India and two research centers in Telangana. The Companyâs segment includes Pharmaceuticals and Agro chemicals. Its Pharmaceuticals segment is engaged in manufacturing and selling of bulk drugs, finished dosage formulations and related services. Its Agro Chemicals is engaged in manufacturing and selling of agro chemical. It manufactures active pharmaceutical ingredients products which are primarily used for captive consumption in its FDF products and are also sold to customers for various international markets such as Brazil, Europe, and United States of America.
Sector
Pharmaceuticals
Calendar
27/05/2024
- Q4 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
1,028
INR
Average target price
975.4
INR
Spread / Average Target
-5.11%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +24.21% | 2.21B | |
| +25.83% | 661B | |
| +26.84% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +14.17% | 231B | |
| +4.67% | 200B | |
| -9.41% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- NATCOPHARM Stock
